BridgeMD
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
EU CTIS ID: 2025-522674-36-00
What this study is testing
To demonstrate whether the primary intervention is superior to the primary control in reducing the occurrence of MALO.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have hepatic steatosis (liver fat), diagnosed with MRI
- Have liver fibrosis, diagnosed with non-invasive tests
- (Liver biopsy not needed for enrollment in this trial)
You likely can't join if
- Have any other type of liver disease other than MASLD
- Have a body mass index (BMI) <25 kilogram per square meter (kg/m2)
- Prior cirrhotic liver disease (history of esophageal / gastric varices, ascites, hepatic encephalopathy, historical diagnosis of cirrhosis on liver biopsy)
- Have lost more than 11 pounds within the 3 months prior to screening
- Have a hemoglobin A1c (HbA1c) greater than 10%
- Have type 1 diabetes
The study team makes the final eligibility decision.
Where it's taking place
- Mexico
- Japan
- Switzerland
- Ukraine
- Israel
- New Zealand
- Taiwan
- Australia
- Malaysia
- United Kingdom
- China
- Canada
- Turkey
- Brazil
- Korea, Republic of
- Argentina
- India
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico; Japan; Switzerland; Ukraine; Israel; New Zealand and 12 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.